MSN Laboratories is an API and finished-dose manufacturer based in India. It holds 269 active US drug master files and 62 valid CEPs. Its filings concentrate with MHRA (UK), DIGEMAPS (DO) and ARCSA (EC). Its GMP standing is certified by ANVISA (Brazil), EMA and MHRA (UK), among 10 authorities. Its most recent recorded inspection, by US FDA, closed on 9 May 2025 as VAI. Customs aggregates show $231.3M of exports covering 3,882 molecules to 89 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Rangareddy, United Arab Emirates | Not on file |
| Telangana, Colombia | Not on file |
| LETCHWORTH GARDEN CITY, United Kingdom | Not on file |
| HITCHIN, United Kingdom | Not on file |
| Rangareddy District, India | 3011033544 |
| Sangareddy, India | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Dapagliflozin | SFDA (Saudi Arabia), US FDA | 9 |
| Posaconazole | SFDA (Saudi Arabia), US FDA | 6 |
| Ruxolitinib | SFDA (Saudi Arabia), US FDA | 6 |
| Bosutinib | SFDA (Saudi Arabia), US FDA | 5 |
| Eplerenone | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Gefitinib | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Tofacitinib | SFDA (Saudi Arabia), US FDA | 5 |
| Abiraterone | SFDA (Saudi Arabia), US FDA | 4 |
| Cabozantinib | US FDA | 4 |
| Capecitabine | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Dasatinib | SFDA (Saudi Arabia), US FDA | 4 |
| Deferasirox | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Docetaxel | EDQM, US FDA | 4 |
| Duloxetine | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Dutasteride | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Ezetimibe | SFDA (Saudi Arabia), US FDA | 4 |
| Fingolimod | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Ibrutinib | US FDA | 4 |
| Lenalidomide | SFDA (Saudi Arabia), US FDA | 4 |
| Mirabegron | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Nilotinib | US FDA | 4 |
| Rosuvastatin | SFDA (Saudi Arabia), US FDA | 4 |
| Sorafenib | SFDA (Saudi Arabia), US FDA | 4 |
| Teriflunomide | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Treprostinil | US FDA | 4 |
| Acalabrutinib | US FDA | 3 |
| Alfuzosin | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Apixaban | SFDA (Saudi Arabia), US FDA | 3 |
| Avanafil | SFDA (Saudi Arabia), US FDA | 3 |
| Azelastine | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MHRA (UK) | 140 | 5 |
| DIGEMAPS (DO) | 104 | None |
| ARCSA (EC) | 101 | None |
| TMDA (TZ) | 94 | None |
| INVIMA (CO) | 86 | 1 |
| ZAMRA (ZM) | 83 | None |
| ANVISA (Brazil) | None | 10 |
| EMA | None | 9 |
| MFDS (Korea) | None | 4 |
| US FDA | None | 4 |
| CDSCO (India) | None | 2 |
| UZPHARM (UZ) | None | 2 |
| EAEU_EEC | None | 1 |
| NAFDAC (NG) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $106.8M | 93 |
| 2025 | Not reported | $231.3M | 89 |
| 2024 | Not reported | $207.9M | 82 |
| 2023 | Not reported | $214.7M | 78 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. MSN Laboratories comes back tiered against every other supplier able to file there.
Start for free